Company Overview
Creation, validation and commercialisation of digital brain health assessments; and Design and provision of quality assurance services in clinical trials, focused on the administration, scoring and recording of conventional brain health assessments.
Website | www.cogstate.com |
---|---|
Head Office | Melbourne VIC |
Registry | Automic Registry Services |
CEO | Bradley O'Connor |
Chair Person | Martyn Myer |
GICS Industry | Health Care Equipment & Services |
Sub Industry | Health Care Technology |
Sector | Health Care |
Market Cap | $258 m |
---|---|
Shares on Issue | 173 m |
Status | Trading |
Last Price | |
Change | |
52 Week H/L | |
VWAP | |
Bid/Ask |
Directors and Management
Mr Martyn Kenneth Myer
Non-Executive Chairman,Non-Executive Director 01/10/1999
Mr Myer sits on the Fishermans Bend board, a Victorian Government board charged with developing the Fishermans Bend precinct, and the boards of the Australian Chamber Orchestra and Watertrust Australia Limited. He previously served as Deputy Chancellor of the Council of the University of Melbourne, President of The Myer Foundation, one of two principle Myer Family philanthropic funds, President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of The Florey Institute of Neuroscience and Mental Health, where he participated in the transition of the Institute's research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases Other directorships and interests held by him are Cogstate Inc., Cogstate Health Inc., Cogstate Sports Pty Ltd and Cogstate Spain SL, Fishermans Bend, the Australian Chamber Orchestra and Watertrust Australia Limited
AO, BE, MESc.(Mon), MSM (MIT), FIE (Aust) Male
Mr Bradley O'Connor
Chief Executive Officer,Managing Director 11/11/2005
Mr O'Connor has responsibility for Cogstate's overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business. Prior to taking the position of CEO at Cogstate in 2005, Mr O'Connor joined Cogstate as Chief Financial Officer and Company Secretary in 2004. Prior to that, Mr O'Connor held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers. Other directorships and interests held by him are at Cogstate Inc., Cogstate Health Inc., Cogstate Sports Pty Ltd, Cogstate Healthcare LLC and Cogstate Spain SL.
B.Bus, CA Chartered accountant Male
Ms Ingrid Anne Player
Non-Executive Director 30/08/2019
Ms Player brings healthcare sector experience and strong commercial expertise to the Board of Cogstate. She has held senior executive roles with Healthscope Ltd, a leading private healthcare provider in Australia, including the former positions of Group Executive Legal, Governance and Sustainability, and General Counsel and Company Secretary from 2005 until 2019. Ms Player also has considerable international commercial and regulatory experience that spans different markets and industries, which she gained in private legal practice in Australia and in The Netherlands. Other directorships and interests held by her are at HealthShare Victoria Cleanaway Waste Management Limited (from 01 March 2021).
BEco, LLB(Homs), GAICD, FGIA Female
Mr Richard van den Broek
Non-Executive Director 26/08/2010
Mr Van Den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. Prior to his time as an investor in the healthcare industry Mr Van Den Broek had a ten year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist.
CFA Male
Mr David Dolby
Non-Executive Director 22/11/2013
Mr Dolby is founder and CEO of Dolby Family Ventures, a venture capital investment firm focused on technology and life sciences investments in neuro technology and therapeutics targeting Alzheimer's disease. He represents the Dolby Family Trust on a number of technology, scientific research, and consumer products investments focusing on innovation and commercialising intellectual property. Other directorships and interests held by him are at Dolby Laboratories (from 2011), Salk Institute for Biological Sciences (from 2019), Academy Museum of Motion Pictures (from 2019), Tipping Point Community (from 2015), CFO of the Ray and Dagmar Dolby Family Fund (since 2010)
BSE, MBA Male
Dr Richard Mohs
Non-Executive Director 20/01/2017
Dr Mohs is currently Chief Scientific Officer for the Global Alzheimer's Platform (GAP) Foundation, a non-profit devoted to enhancing the speed and quality of Alzheimer's disease research. He also serves as a consultant to academic institutions, foundations and biopharmaceutical companies, and is a member of the Board of Governors for the Alzheimer's Drug Discovery Foundation. Dr Mohs retired from Eli Lilly in 2015, where he held leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer's Drug Development Team. Before joining Eli Lilly, Dr Mohs spent 23 years with the Mount Sinai School of Medicine where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Centre. Other directorships and interests held by him are at Alzheimer's Drug Discovery Foundation, Chief Science Officer, Global Alzheimer's Platform Foundation, Consultant for various biotechnology companies, academic institutions and foundations
PhD(Psychology), PostDoc(Pharmacology) Male
Ms Kim Wenn
Non-Executive Director 30/11/2020
Ms Wenn brings technology experience and strong commercial expertise to the Board of Cogstate, with over 30 years experience in innovation roles. Until July 2018, she held the role of Chief Information Officer at Tabcorp Holdings, an ASX50 listed company where Kim led a team of 1,200 technology experts to drive strategic direction through digital transformation. Her experience includes, among other things, business strategy, governance and change management with a focus on digital disruption. She was a director at Volt Bank Limited.
BCompSci,AMP,GMAICD Female
Top 20 Shareholders
Name | Shares | % | |
---|---|---|---|
1. | National Nominees Limited | 28,947,551 | 16.90 |
2. | Dagmar Dolby | 21,754,028 | 12.70 |
3. | Citicorp Nominees Pty Limited | 21,055,219 | 12.30 |
4. | Myer & Myer Pty Ltd | 14,424,569 | 8.40 |
5. | HSBC Custody Nominees (Australia) Limited | 14,036,981 | 8.20 |
6. | Nebula Neuro Pty Ltd | 8,000,000 | 4.70 |
7. | Anacacia Pty Limited | 6,771,764 | 4.00 |
8. | Mpyer Investments Pty Ltd | 6,061,872 | 3.50 |
9. | BNP Paribas Nominees Pty Ltd | 3,906,382 | 2.30 |
10. | Mr Bradley John O'Connor | 2,705,929 | 1.60 |
11. | Myer & Myer Pty Ltd I | 2,563,000 | 1.50 |
12. | David Dolby Investments Ii Llc | 2,202,274 | 1.30 |
13. | Dr Peter Anthony Bick & Ms Melanie Jo Gribble | 1,881,026 | 1.10 |
14. | Merrill Lynch (Australia) Nominees Pty Limited | 1,833,081 | 1.10 |
15. | Dagmar Dolby I | 1,776,500 | 1.00 |
16. | Mr Alistair David Strong | 1,320,000 | 0.80 |
17. | Mutual Trust Pty Ltd | 1,283,806 | 0.80 |
18. | Beta Gamma Pty Ltd | 1,220,000 | 0.70 |
19. | Mr David Alexander Simpson & Mrs Dawn Gentry Simpson | 1,163,689 | 0.70 |
20. | Alexander 2006 Llc | 1,059,138 | 0.60 |
Director Transactions
Date | Name | Qty | Value | Direction | Notes |
---|---|---|---|---|---|
12/10/2021 | Richard van den Broek | 100,000 | $84,000 | Buy | Exercise of options. |
12/10/2021 | Richard van den Broek | 100,000 | $84,000 | Exercise | Exercise of options. |
14/09/2021 | Martyn Myer | 250,000 | $442,733 | Sell | On-market trade. Average Price |
10/09/2021 | Martyn Myer | 200,000 | $168,000 | Exercise | Exercise of options. |
10/09/2021 | Martyn Myer | 200,000 | $168,000 | Buy | Exercise of options. As per announcement on 15/09/2021 |
10/09/2021 | David Dolby | 100,000 | $84,000 | Exercise | Exercise of options. |
10/09/2021 | David Dolby | 100,000 | $84,000 | Buy | Exercise of options. |
01/09/2021 | Kim Wenn | 11,686 | $20,167 | Buy | On-market trade. Average Price |
23/03/2021 | Bradley O'Connor | 750,000 | $630,000 | Exercise | Exercise of options. |
23/03/2021 | Bradley O'Connor | 750,000 | $630,000 | Buy | Exercise of options. |
09/03/2021 | Bradley O'Connor | 2,250,000 | $2,025,000 | Sell | On-market trade. |
02/11/2020 | Bradley O'Connor | 1,250,000 | $1,387,500 | Issued | Issue of options. |
22/10/2020 | Richard van den Broek | 50,000 | $13,000 | Exercise | Exercise of options. |
22/10/2020 | Richard van den Broek | 50,000 | $13,000 | Issued | Exercise of options. |
22/10/2020 | David Dolby | 100,000 | $26,000 | Exercise | Exercise of options. |
22/10/2020 | David Dolby | 100,000 | $26,000 | Issued | Exercise of options. |